comparemela.com

Latest Breaking News On - Y mabs - Page 1 : comparemela.com

Y-maBs Therapeutics Class Action Lawsuit Announced: Johnson

SAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on.

New yorkUnited statesJohnson fistelJim bakerY mabs therapeutics incY mabs therapeuticsClass periodCentral german childhood cancer registryY mabsLass action

Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) Investor Update:

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing its investigation of claims on behalf of.

New yorkUnited statesNew jerseyLaurenced kingLos angelesJeffreyp campisiKaplan foxY mabs therapeutics incDrug administrationKaplan fox kilsheimerY mabs therapeuticsBiologics license applicationOncologic drugs advisory committee meetingAttorney advertisingKaplan fox amp kilsheimer llpY mabs

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022 DANYELZA marketing authorization

New yorkUnited statesAdium pharmaGlobe newswirey mabs therapeutics incOncologic drugs advisory committeeInternational society of pediatric oncologyY mabs therapeutics incAbs therapeuticsThomas gadInterim chief executiveRecent corporateDrugs advisory committeeInternational societyPediatric oncologyMemorial sloan ketteringReview voucher

Y-mAbs Therapeutics Investigated by Block & Leviton For

BOSTON , Oct. 26, 2022 (GLOBE NEWSWIRE) Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law.

United statesY mabs therapeutics incDrug administrationBlock levitonY mabs therapeuticsBiologics license applicationBlock amp leviton llpY mabsEfuse to fileLass action

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,

New yorkUnited statesGlobe newswirey mabs therapeutics incUs federal drug administrationBrazilian health regulatory agencyY mabs therapeutics incResearchers at memorial sloan kettering cancer centerAbs therapeuticsNacional de vigilThomas gadInterim chief executiveMemorial sloan kettering cancer centerDrug administrationBoxed warningPrescribing informationPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.